Modulate Bio

Modulate Bio is a private, pre-revenue biotech founded in 2021, leveraging a proprietary platform to design selective GABA-A PAMs for neurological disorders. The company is nearing a development candidate for Essential Tremor, its lead program, with a pipeline that includes epilepsy and anxiety. Backed by academic roots from Harvard and Brigham and Women's Hospital, the team combines deep drug discovery expertise with a clear focus on validated targets with significant unmet medical need.

Proprietary platform for designing novel, differentiated GABA-A positive allosteric modulators (PAMs) with controlled activation of specific receptor subunits to separate efficacy from side effects.

Competition includes other biotechs developing next-generation GABA modulators (e.g., Sage Therapeutics' zuranolone, though for depression, and others in discovery). The primary competition in Essential Tremor is from generic, poorly tolerated drugs (propranolol, primidone) and invasive devices/surgery, representing a low bar for a novel, effective oral therapy.